Evidence map›Paper›PMID 30233808›Full record

ArticleBMJ open sport & exercise medicine2018

Exercise performance after salbutamol inhalation in non-asthmatic, non-athlete individuals: a randomised, controlled, cross-over trial.

Filip Eckerström, Christian Emil Rex, Marie Maagaard, Sune Rubak, Vibeke Elisabeth Hjortdal, Johan Heiberg

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in BMJ open sport & exercise medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02914652 (The Cardiopulmonary Effect of Inhaled Beta-2-agonists on Adult Ventrucular Septal Defect Patients With Persistant or Surgically Corrected Conditions - The VENTI Trial), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02914652 phase4completednot on this map

The Cardiopulmonary Effect of Inhaled Beta-2-agonists on Adult Ventrucular Septal Defect Patients With Persistant or Surgically Corrected Conditions - The VENTI Trial

TypeinterventionalSponsorUniversity of AarhusRan2016 to 2018Enrolled96ConditionsVentricular Septal DefectArmsSalbutamol, Norflouran (Placebo Evohaler(R) )
3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Filip EckerströmDepartment of Cardiothoracic and Vascular Surgery, Aarhus University Hospital, Aarhus, Denmark.
Christian Emil RexDepartment of Cardiothoracic and Vascular Surgery, Aarhus University Hospital, Aarhus, Denmark.
Marie MaagaardDepartment of Cardiothoracic and Vascular Surgery, Aarhus University Hospital, Aarhus, Denmark.
Sune RubakDepartment of Clinical Medicine, Aarhus University Hospital, Aarhus, Denmark.
Vibeke Elisabeth HjortdalDepartment of Cardiothoracic and Vascular Surgery, Aarhus University Hospital, Aarhus, Denmark.
Johan HeibergDepartment of Cardiothoracic and Vascular Surgery, Aarhus University Hospital, Aarhus, Denmark.
Aarhus University Hospital · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAsthma is a frequent diagnosis in competitive sports, and inhaled β

objectiveTo investigate the effect of inhaled β

methodsIn a double-blinded, placebo-controlled, cross-over trial, healthy, non-asthmatic, non-athlete individuals were randomised to inhalation of either 900 µg of salbutamol or placebo. Cardiopulmonary exercise testing, dynamic spirometry and impulse oscillometry were performed. The primary outcome was the effect from salbutamol on peak oxygen uptake, whereas secondary outcomes were breathing reserve and ventilation efficiency, and workload, heart rate, breath rate and minute ventilation at peak exercise under influence of salbutamol.

resultsA total of 36 healthy subjects with a mean age of 26±5 years were included. Salbutamol had no effect on peak oxygen uptake compared with placebo, 46.8±1.3 mL/kg/min versus 46.6±1.2 mL/kg/min, p=0.64. Salbutamol had no effect on workload, p=0.20, heart rate, p=0.23, breath rate, p=0.10, or minute ventilation, p=0.26, at peak exercise compared with placebo. Salbutamol lowered oxygen uptake, p=0.04, and workload, p=0.04, at anaerobic threshold compared with placebo. Forced expiratory volume in 1 s, 116%±13% of predicted, and peak expiratory flow, 122%±16% of predicted, increased after inhalation of salbutamol compared with placebo; 109%±13% and 117%±17%, respectively, p<0.01. Breathing reserve was found to be higher, 22%±2%, after salbutamol inhalation than after placebo, 16%±2%, p<0.01.

conclusionInhaled salbutamol did not improve peak oxygen uptake in healthy, non-asthmatic, non-athlete individuals compared with placebo. TRIAL REGISTRATION NUMBER: NCT02914652.

Indexed as

dopingenduranceperformancerandomised controlled trialSports & exercise medicine

Identifiers

PMID30233808
PMCPMC6135409
OpenAlexW2889426593

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.